Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What Happens on May 31
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(256)
•••
Comment by GameChangerBeton May 26, 2021 8:49am
183 Views
Post# 33266466

RE:RE:RE:What Happens on May 31

RE:RE:RE:What Happens on May 31
StockingUp21 wrote:

The only hurdle is guy who you just heard from. 

 

Forestview wrote: Actually just heard from Dan.  So, the MC will increase as it absorbs AH.  How the market reacts will drive share price.  Hopefully this is the last hurdle holding this stock down.  

 

 




Do you have any inventory in your vocabulary other than "dilution" "pumper" "Dan this Dan that" ? This is the only basis of your posts in it's totality.

Do you comprehend the stupidity and foolishness of being so negative about an investment or a significant aspect of it to the point where your entire repertoire consists of nothing but negative sentiment but still maintaining your position in that investment.

-Management is terrible
-Nothing but delays
-Nothing but pumperes
-Nothing but dilution
Coclusion: Let me keep my money there. 
Foolishness

Come with some intellect, and articulate that intelligence in a way that's understood. Provide something of substance that can add value.
Or
Take a step back, have a seat, and please, stop talking during the movie, others are trying to pay attention.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities